Product Description
Mechanisms of Action: 5-HT4 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Heart Failure|Atrial Fibrillation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2005-004487-22 | P2 |
Completed |
Heart Failure |
2007-07-17 |
|
NCT00041496 | P2 |
Completed |
Atrial Fibrillation |
2003-12-01 |
|
BMI 001 / SMR-1389 | P2 |
Completed |
Heart Failure |
None |